On January 8, 2026, InflaRx N.V. announced a 30% workforce reduction to cut costs, resulting in an estimated one-time charge of $7 million, mainly from inventory write-offs. This restructuring aims to extend its cash runway into mid-2027 while continuing its clinical study for Gohibic (vilobelimab).